RE:RE:Phase 1/2 AMBUSH Trial November 07. 2022 - GSK’s Blenrep (belantamab mafodotin) missed on its Phase III DREAMM-3 trial for relapsed or refractory multiple myeloma (RRMM), the company announced Monday, possibly putting the drug’s continued approval at risk.
The DREAMM-3 study was a head-to-head superiority study that evaluated Blenrep alone compared to pomalidomide in combination with low-dose dexamethasone (PomDex). It failed to hit the primary endpoint of progression-free survival (PFS).
In the study, the median PFS for Blenrep was 11.2 months compared to 7 months for PomDex. Secondary endpoints included overall response rate (ORR), duration of response (DOR) and overall survival (OS). ORR was 41% for Blenrep, compared to 36% for PomDex. No new safety issues were identified.
https://www.biospace.com/article/gsk-s-multiple-myeloma-drug-blenrep-misses-mark-in-confirmatory-trial/